Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $57.8 million.

  • Denali Therapeutics' Cash from Investing Activities fell 3825.21% to $57.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $406.7 million, marking a year-over-year increase of 31643.71%. This contributed to the annual value of -$88.8 million for FY2024, which is 13560.09% down from last year.
  • Denali Therapeutics' Cash from Investing Activities amounted to $57.8 million in Q3 2025, which was down 3825.21% from $157.9 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Cash from Investing Activities registered a high of $172.2 million during Q4 2024, and its lowest value of -$453.2 million during Q1 2024.
  • In the last 5 years, Denali Therapeutics' Cash from Investing Activities had a median value of $57.8 million in 2025 and averaged $12.2 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 55444.58% in 2023, then plummeted by 38879.58% in 2024.
  • Quarter analysis of 5 years shows Denali Therapeutics' Cash from Investing Activities stood at -$40.8 million in 2021, then crashed by 213.03% to -$127.6 million in 2022, then skyrocketed by 157.27% to $73.0 million in 2023, then soared by 135.75% to $172.2 million in 2024, then plummeted by 66.42% to $57.8 million in 2025.
  • Its last three reported values are $57.8 million in Q3 2025, $157.9 million for Q2 2025, and $18.7 million during Q1 2025.